A revolution in technology has moved genetic studies forward at a remarkable pace over the last 5 years, and clear genetic contributions to smoking behavior have been identified. Our group was the first to report the association of nicotine dependence with the chromosome 15q25.1 region, which includes the CHRNA5-CHRNA3-CHRNB4 cholinergic nicotine receptor subunit genes. The strongest genetic association findings for nicotine dependence, lung cancer and chronic obstructive pulmonary disease then converged to implicate this region. Our studies and several meta-analyses have convincingly shown that SNPs in the CHRNA6-CHRNB3 receptor subunits and nicotine metabolizing gene CYP2A6 are also associated with heavy smoking and nicotine dependence. The goal of this project is to further identify and characterize genetic findings for nicotine dependence and to integrate how these associations contribute to successful smoking cessation.
Specific Aim 1 is to catalogue, characterize, and test identified variants and fine map nicotinic receptor genes and nicotine metabolizing genes.
This aim will build upon custom targeted sequencing from the Center for Inherited Disease Research (CIDR) to catalogue variation in the nicotinic receptors and nicotine metabolizing genes in almost 3,000 nicotine dependent or non-dependent subjects.
Specific Aim 2 is to evaluate genetic associations for nicotine dependence in large-scale studies, including our own replication sample and through participation in meta-analyses and consortia.
Specific Aim 3 is to evaluate genetic associations for smoking cessation in large-scale studies. We will actively generate and participate in meta-analyses and consortia assessing smoking cessation related phenotypes, and we will also build upon our collaboration with Dr. Timothy Baker, who has data from smoking cessation trials along with phenotypic and genetic data from the Pfizer clinical trial of varenicline (Chantix(R)). This project will continueto accelerate the discovery of variation in molecular pathways that govern the development of nicotine dependence and extend our work toward the understanding of smoking cessation. By capitalizing on the resources and collaborations we have previously developed, this study will take an important next step along the cutting edge of genomic science and move the field to the next level of understanding the genetics of nicotine dependence and smoking cessation.

Public Health Relevance

Tobacco use is the leading preventable cause of premature death in the United States and the world. Smoking behavior is significantly influenced by variation in the human genome. The goal of this project is to better understand the genetic factors that affect nicotine addiction and thus the ability to quit smoking.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA036583-01A1
Application #
8722284
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Rutter, Joni
Project Start
2014-05-01
Project End
2018-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$745,315
Indirect Cost
$221,748
Name
Washington University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Schwantes-An, Tae-Hwi; Zhang, Juan; Chen, Li-Shiun et al. (2016) Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behav Genet 46:151-69
Chen, Li-Shiun; Horton, Amy; Bierut, Laura (2016) Pathways to precision medicine in smoking cessation treatments. Neurosci Lett :
Chen, Li-Shiun; Baker, Timothy; Hung, Rayjean J et al. (2016) Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. EBioMedicine 11:219-226
Olfson, Emily; Cottrell, Catherine E; Davidson, Nicholas O et al. (2015) Identification of Medically Actionable Secondary Findings in the 1000 Genomes. PLoS One 10:e0135193
Hancock, Dana B; Wang, Jen-Chyong; Gaddis, Nathan C et al. (2015) A multiancestry study identifies novel genetic associations with CHRNA5 methylation in human brain and risk of nicotine dependence. Hum Mol Genet 24:5940-54
Chen, Li-Shiun; Baker, Timothy B; Bierut, Laura J (2015) The value of control conditions for evaluating pharmacogenetic effects. Pharmacogenomics 16:2005-6
Hancock, Dana B; Levy, Joshua L; Gaddis, Nathan C et al. (2015) Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. Biol Psychiatry 78:474-84
Chen, Li-Shiun; Hung, Rayjean J; Baker, Timothy et al. (2015) CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. J Natl Cancer Inst 107:
Hancock, D B; Reginsson, G W; Gaddis, N C et al. (2015) Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Transl Psychiatry 5:e651
Chen, Li-Shiun; Baker, Timothy B; Jorenby, Douglas et al. (2015) Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend 154:278-82

Showing the most recent 10 out of 11 publications